Prof. Başak Oyan Uluç is a medical oncologist and professor with a medical degree from Yeditepe University (2012). She brings extensive clinical experience, most recently serving with Acıbadem Health Group since 2023, where she focuses on evidence-based cancer care and multidisciplinary patient management. Her professional activities are supported by active memberships in leading national and international organizations, including the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the Turkish Society of Medical Oncology (TTOD), the Turkish Hematology Association (THD), the Turkish Internal Medicine Specialty Society, the Istanbul Medical Chamber of the Turkish Medical Association, the Istanbul Breast Diseases Association, and the Turkish Oncology Group Association (TOG). Known for combining clinical expertise with collaborative research and education, she is committed to advancing oncology practice, improving patient outcomes, and contributing to professional development within the oncology community.
Education
- 2012 Yeditepe University Faculty of Medicine/ Professor
- 2006 Yeditepe University Faculty of Medicine / Associate Professor
- 2004 Hacettepe University Faculty of Medicine Medical Oncology
- 2004 European Certification in Medical Oncology
- 2001 Hacettepe University Faculty of Medicine Internal Medicine
- 1996 Hacettepe University Faculty of Medicine
Experience
- 2021 – 2024 Oncology and Immunotherapy Association/ President
- 2023 Acibadem Health Group
- 2017 Dana Farber/Partners Cancer Care Oncology Visiting Physician Program, Boston
- 2017 Acibadem University Faculty of Medicine/ Professor
- 2016 Acibadem Health Group
- 2014 – 2016 Turkish Society of Medical Oncology (TTOD)/ Secretary General
- 2012 – 2016 Yeditepe University Faculty of Medicine/ Professor
- 2006 – 2012 Yeditepe University Faculty of Medicine /Doctor
- 2004 – 2006 Yeditepe University Faculty of Medicine /Doctor
- 2001 – 2004 Hacettepe University Oncology Institute// Medical Oncology
- 2000 – 2001 Hacettepe University Oncology Institute// Medical Oncology
- 1997 – 2001 Hacettepe University Faculty of Medicine/ Internal Medicine
- 1996 Hacettepe University Faculty of Medicine/ Internal Medicine
Memberships
- Europen Society of Medical Oncology (ESMO)
- Turkish Society of Medical Oncology (TTOD)
- American Society of Clinical Oncology (ASCO)
- Turkish Hematology Association (THD)
- Turkish Internal Medicine Specialty Society
- Turkish Medical Association, Istanbul Medical Chamber
- Istanbul Breast Diseases Association
- Turkish Oncology Group Association (TOG)
Publications
- Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
BMC Cancer. 2024 Jan 2;24(1):16. - A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small celi lung cancer patients and crizotinib efficacy
Lung Sub-Group Study of the Turkish Oncology Group. Medicine (Baltimore). 2024 May 24;103(21):e3797 - Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study
Expert Opin Pharmacother. 2024 Mar; 25(4):477-484. - Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2- negative metastatic breast cancer
Future Oncol. 2023 May 3. - Immunotherapy for Lung Cancer
J Oncol Sci. 2023;9(2):97-111. - Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group
Current Problems in Cancer, 2023 Dec; 47 (6): 101017 - Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
BMC Cancer (2023) 23:136. - A Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) Study
J Cancer Res Clin Oncol. 2022 Apr 5. - Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small celi lung cancer: a real-life data of the Turkish Oncology Group
J Cancer Res Clin Oncol. 2022 Jun - The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locaily advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study
Anticancer Drugs. 2022 Aug 1 ;33(7):663-670
